Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Sy

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru to Present at the GLP-1 Based Therapeutics Summit
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
Veru Announces Date of 2024 Annual Meeting of Shareholders
Veru Reschedules Annual Meeting of Shareholders
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.